104 related articles for article (PubMed ID: 12638901)
1. Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies.
Gharavi AE; Pierangeli SS; Harris EN
Immunobiology; 2003; 207(1):37-42. PubMed ID: 12638901
[TBL] [Abstract][Full Text] [Related]
2. Origin of antiphospholipid antibodies.
Gharavi AE; Pierangeli SS; Harris EN
Rheum Dis Clin North Am; 2001 Aug; 27(3):551-63. PubMed ID: 11534259
[TBL] [Abstract][Full Text] [Related]
3. New developments in viral peptides and APL induction.
Gharavi AE; Pierangeli SS; Harris EN
J Autoimmun; 2000 Sep; 15(2):227-30. PubMed ID: 10968915
[TBL] [Abstract][Full Text] [Related]
4. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo.
Gharavi AE; Pierangeli SS; Espinola RG; Liu X; Colden-Stanfield M; Harris EN
Arthritis Rheum; 2002 Feb; 46(2):545-52. PubMed ID: 11840458
[TBL] [Abstract][Full Text] [Related]
5. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies.
Gharavi AE; Vega-Ostertag M; Espinola RG; Liu X; Cole L; Cox NT; Romagnoli P; Labat K; Pierangeli SS
Lupus; 2004; 13(1):17-23. PubMed ID: 14870913
[TBL] [Abstract][Full Text] [Related]
6. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro.
Gharavi AE; Pierangeli SS; Colden-Stanfield M; Liu XW; Espinola RG; Harris EN
J Immunol; 1999 Sep; 163(5):2922-7. PubMed ID: 10453040
[TBL] [Abstract][Full Text] [Related]
7. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
Arnout J
Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
[TBL] [Abstract][Full Text] [Related]
8. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo.
Pierangeli SS; Blank M; Liu X; Espinola R; Fridkin M; Ostertag MV; Roye-Green K; Harris EN; Shoenfeld Y
J Autoimmun; 2004 May; 22(3):217-25. PubMed ID: 15041042
[TBL] [Abstract][Full Text] [Related]
9. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides.
Gharavi EE; Chaimovich H; Cucurull E; Celli CM; Tang H; Wilson WA; Gharavi AE
Lupus; 1999; 8(6):449-55. PubMed ID: 10483013
[TBL] [Abstract][Full Text] [Related]
10. Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype.
Pierangeli SS; Espinola R; Liu X; Harris EN; Salmon JE
Arthritis Rheum; 2001 Apr; 44(4):876-83. PubMed ID: 11315927
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
[TBL] [Abstract][Full Text] [Related]
12. Origin of antiphospholipid antibodies: induction of aPL by viral peptides.
Gharavi AE; Pierangeli SS
Lupus; 1998; 7 Suppl 2():S52-4. PubMed ID: 9814674
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway.
Yasuda S; Bohgaki M; Atsumi T; Koike T
Immunobiology; 2005; 210(10):775-80. PubMed ID: 16325497
[TBL] [Abstract][Full Text] [Related]
14. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies.
Pierangeli SS; Vega-Ostertag M; Harris EN
Thromb Res; 2004; 114(5-6):467-76. PubMed ID: 15507280
[TBL] [Abstract][Full Text] [Related]
15. Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice.
Manukyan D; Müller-Calleja N; Jäckel S; Luchmann K; Mönnikes R; Kiouptsi K; Reinhardt C; Jurk K; Walter U; Lackner KJ
J Thromb Haemost; 2016 May; 14(5):1011-20. PubMed ID: 26786324
[TBL] [Abstract][Full Text] [Related]
16. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome.
Pierangeli SS; Vega-Ostertag M; Liu X; Girardi G
Ann N Y Acad Sci; 2005 Jun; 1051():413-20. PubMed ID: 16126983
[TBL] [Abstract][Full Text] [Related]
17. Antiphospholipid syndrome (APS): where does it come from?
Sherer Y; Blank M; Shoenfeld Y
Best Pract Res Clin Rheumatol; 2007 Dec; 21(6):1071-8. PubMed ID: 18068862
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
19. Antiphospholipid antibodies: lessons from the bench.
Koike T; Bohgaki M; Amengual O; Atsumi T
J Autoimmun; 2007; 28(2-3):129-33. PubMed ID: 17383159
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.
Otomo K; Atsumi T; Amengual O; Fujieda Y; Kato M; Oku K; Horita T; Yasuda S; Koike T
Arthritis Rheum; 2012 Feb; 64(2):504-12. PubMed ID: 21953404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
